MBio Diagnostics, Inc.

MBio Diagnostics presents tuberculosis study results

Boulder, CO, March 11, 2014 – MBio Diagnostics, Inc. presented results last week of a study entitled "Highly Multiplexed Detection of Antibodies in Whole Blood during Tuberculosis Infection" at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, MA. MBio is collaborating with the Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland, on a program aimed at developing a simple, point-of-care blood test for active tuberculosis disease (TB) using MBio's multiplexed immunoassay platform.

Read More →

MBio Diagnostics and FIND complete Phase I of TB serology program

Boulder, CO, April 22, 2013 – MBio Diagnostics, Inc. announced that it has been collaborating with the Foundation for Innovative New Diagnostics (FIND) on a tuberculosis (TB) serology feasibility project. The project seeks to determine if a set of M. tuberculosis (Mtb) antigens could be useful for serodiagnosis of active TB disease in a point-of-care (POC) assay format. FIND is using MBio’s unique multiplexed immunoassay platform to deliver antibody reactivity results for a panel of 57 Mtb proteins using a single 10-microliter whole blood sample from individuals with suspected TB infection. Phase I of the clinical evaluation, conducted in Vietnam and Peru, concluded in February 2013. Phase II, which represents a larger clinical study, began in March 2013.

Read More →

Page 1 of 1 · Total posts: 2